Comparative Pharmacology
Head-to-head clinical analysis: ANSPOR versus CEFADROXIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANSPOR versus CEFADROXIL.
ANSPOR vs CEFADROXIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Cefadroxil is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking.
250-500 mg orally every 6 hours for 10-14 days; maximum 4 g/day.
1-2 g orally once daily or divided into two doses every 12 hours.
None Documented
None Documented
1.5–2 hours in adults with normal renal function; prolonged to 20–30 hours in severe renal impairment (CrCl <10 mL/min)
Clinical Note
moderateCefadroxil + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefadroxil."
Clinical Note
moderateCefadroxil + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefadroxil."
Clinical Note
moderateWarfarin + Cefadroxil
"Warfarin may increase the anticoagulant activities of Cefadroxil."
Clinical Note
moderatePhenprocoumon + Cefadroxil
Terminal elimination half-life 1.1-1.5 hours in normal renal function; prolonged to 20-30 hours in end-stage renal disease (CrCl <10 mL/min).
Primarily renal (90–95%) as unchanged drug via glomerular filtration and tubular secretion; biliary excretion negligible (<1%)
Primarily renal (90-95% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal (<5%).
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"Phenprocoumon may increase the anticoagulant activities of Cefadroxil."